• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Syndax Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

    6/26/25 8:54:52 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNDX alert in real time by email
    8-K
    0001395937false00013959372025-06-242025-06-24

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 24, 2025

     

     

    SYNDAX PHARMACEUTICALS, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-37708

    32-0162505

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    730 THIRD AVENUE

    FLOOR 9

     

    NEW YORK, New York

     

    10017

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (781) 419-1400

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock

     

    SNDX

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On June 24, 2025, William Meury notified Syndax Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”) due to his acceptance of the role of President and Chief Executive Officer and a member of the Board of Directors at Incyte Corporation, the Company’s collaboration partner for Niktimvo™ (axatilimab-csfr). Mr. Meury’s resignation from the Board is effective June 24, 2025, and is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    SYNDAX PHARMACEUTICALS, INC.

     

     

     

     

    Date:

    June 26, 2025

    By:

    /s/ Michael A. Metzger

     

     

     

    Michael A. Metzger
    Chief Executive Officer

     


    Get the next $SNDX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNDX

    DatePrice TargetRatingAnalyst
    8/5/2025$43.00 → $56.00Buy
    BTIG Research
    7/10/2025$18.00Buy
    Goldman
    10/24/2024$37.00Buy
    UBS
    6/28/2024$37.00Buy
    Jefferies
    1/31/2024$36.00 → $23.00Sector Outperform → Sector Perform
    Scotiabank
    12/22/2023$45.00Buy
    Mizuho
    10/25/2023$29.00Buy
    BofA Securities
    10/11/2023$30.00Buy
    Goldman
    More analyst ratings

    $SNDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REVUFORJ issued to SYNDAX PHARMACEUTICALS INC

    Submission status for SYNDAX PHARMACEUTICALS INC's drug REVUFORJ (ORIG-1) with active ingredient REVUMENIB has changed to 'Approval' on 11/15/2024. Application Category: NDA, Application Number: 218944, Application Classification: Type 1 - New Molecular Entity

    11/18/24 9:22:42 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2025 the Company granted inducement awards to purchase up to 48,600 shares of common stock to seven new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About

    8/6/25 4:01:00 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

    – $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 – – $36.2 million of Niktimvo™ (axatilimab-csfr) net revenue reported by Incyte in first full quarter of launch; $9.4 million in collaboration revenue reported by Syndax – – sNDA in R/R mNPM1 AML granted Priority Review; PDUFA action date of October 25, 2025 – – $517.9 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today repor

    8/4/25 4:01:00 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

    NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2025 financial results and provide a business update on Monday, August 4, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, August 4, 2025. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following: Conference

    7/28/25 7:00:00 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Goldan Keith A. bought 3,000 shares, increasing direct ownership by 3% to 93,746 units (SEC Form 4)

    4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

    5/19/25 4:04:07 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Head of R&D, CMO Botwood Nicholas A.J. bought $105,826 worth of shares (11,765 units at $8.99), increasing direct ownership by 50% to 35,165 units (SEC Form 4)

    4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

    5/19/25 4:03:03 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Huber Martin H. Jr. bought $44,950 worth of shares (5,000 units at $8.99), increasing direct ownership by 7% to 79,000 units (SEC Form 4)

    4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

    5/19/25 4:02:03 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research reiterated coverage on Syndax Pharmaceuticals with a new price target

    BTIG Research reiterated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $56.00 from $43.00 previously

    8/5/25 9:58:18 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Syndax Pharmaceuticals with a new price target

    Goldman initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $18.00

    7/10/25 9:00:59 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Syndax Pharmaceuticals with a new price target

    UBS initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $37.00

    10/24/24 6:28:31 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $SNDX
    SEC Filings

    View All

    Director Podlesak Dennis sold $875,100 worth of shares (57,600 units at $15.19) and exercised 57,600 shares at a strike of $7.20 (SEC Form 4)

    4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

    8/18/25 5:02:20 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Goldan Keith A. acquired $10,335 worth of shares (1,226 units at $8.43), increasing direct ownership by 1% to 93,676 units (SEC Form 4)

    4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

    8/7/25 5:30:22 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Metzger Michael A sold $69,953 worth of shares (7,534 units at $9.29), decreasing direct ownership by 2% to 298,661 units (SEC Form 4)

    4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

    7/18/25 4:30:04 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Syndax Pharmaceuticals Inc.

    144 - Syndax Pharmaceuticals Inc (0001395937) (Subject)

    8/18/25 4:36:39 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Syndax Pharmaceuticals Inc.

    144 - Syndax Pharmaceuticals Inc (0001395937) (Subject)

    8/14/25 4:26:19 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Syndax Pharmaceuticals Inc.

    SCHEDULE 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

    8/13/25 5:52:51 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNDX
    Leadership Updates

    Live Leadership Updates

    View All

    Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

    - Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Dr. Nicholas Botwood BSc (Hons), MBBS, MFPM, FRCP, to the role of Head of Research and Development (R&D) and Chief Medical Officer. Dr. Botwood brings to Syndax over 25 years of industry experience, most recently serving as the Head of Worldwide Medical Oncology at Bristol Myers Squibb, where he oversa

    5/12/25 4:01:00 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

    BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) since 2015. "We are delighted to have Michael, a proven leader in our industry with a robust track record of success, join the board," said Lara S. Sullivan, M.D., President and Chief Ex

    6/10/24 7:30:00 AM ET
    $PYXS
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors

    WALTHAM, Mass., May 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Aleksandra Rizo, M.D., Ph.D., to its Board of Directors. Dr. Rizo has extensive clinical development experience and a track record of successfully leading the development of several hematology drugs from discovery through commercialization. She will serve as a member of the Science and Technology Committee of the Board. Dr. Rizo will replace Dr. Briggs Morrison who will step down effective May 14, 2024 after a successful 9-year tenure as a member of the Company's Board of Directo

    5/15/24 4:05:00 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNDX
    Financials

    Live finance-specific insights

    View All

    Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

    – $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 – – $36.2 million of Niktimvo™ (axatilimab-csfr) net revenue reported by Incyte in first full quarter of launch; $9.4 million in collaboration revenue reported by Syndax – – sNDA in R/R mNPM1 AML granted Priority Review; PDUFA action date of October 25, 2025 – – $517.9 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today repor

    8/4/25 4:01:00 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

    NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2025 financial results and provide a business update on Monday, August 4, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, August 4, 2025. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following: Conference

    7/28/25 7:00:00 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

    – $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch – – $13.6 million in Niktimvo™ (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of launch – – Submitted sNDA for revumenib in R/R mNPM1 AML – – Initiated a pivotal frontline trial of revumenib plus ven/aza in mNPM1 and KMT2Ar AML – – $602.1 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, toda

    5/5/25 4:01:00 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

    SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

    11/8/24 10:52:38 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

    SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

    10/18/24 11:49:10 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Syndax Pharmaceuticals Inc.

    SC 13G - Syndax Pharmaceuticals Inc (0001395937) (Subject)

    2/14/24 12:50:09 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care